secwatch.observer — SEC 8-K summary
======================================

Issuer:     MBX Biosciences, Inc. (MBX)
CIK:        0001776111
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0000950170-25-104602
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MBX Biosciences Q2 net loss $19.4M; cash $224.9M; canvuparatide Phase 2 data on track for Q3 2025
--------------------------------------------------------------------------------

- Net loss $19.4M for Q2 2025 vs $15.9M in Q2 2024; R&D expenses increased to $17.7M.
- Cash, equivalents and marketable securities $224.9M as of June 30, 2025; expected to fund operations into mid-2027.
- Phase 2 Avail trial of canvuparatide in hypoparathyroidism topline results expected in Q3 2025.
- Phase 2a trial of imapextide (post-bariatric hypoglycemia) and Phase 1 trial of MBX 4291 (obesity) to initiate in Q3 2025.
- Appointed Dr. Andreas Moraitis as SVP of Clinical Development in June 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1776111/000095017025104602/0000950170-25-104602-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1776111/000095017025104602/mbx-20250807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-104602

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer